EVERSANA®, a leading global commercial services provider to the life sciences industry, and Pulse Infoframe Inc., a real-world evidence (RWE) and data generation platform partner, have announced a strategic partnership to provide end-to-end real-world data and Health Economics and Outcomes Research (HEOR) solutions for biopharmaceutical and medical device manufacturers worldwide.
The alliance integrates EVERSANA’s global commercial infrastructure, market access capabilities, and HEOR advisory services with Pulse Infoframe’s regulatory-grade RWE platform. Pulse Infoframe specializes in designing and managing disease registries, natural history studies, and extracting regulatory-grade clinical data directly from specialized sites and patient cohorts. By coupling these capabilities with EVERSANA’s analytics, evidence synthesis, and reimbursement strategy, the partnership enables life sciences companies to generate robust clinical and economic evidence across all stages of the product lifecycle—from early development and health technology assessments (HTA) to post-launch market adoption.
Dr. Femida Gwadry-Sridhar, Chief Executive Officer and Founder of Pulse Infoframe, highlighted the impact of the collaboration:
“Working with EVERSANA connects that evidence to the regulatory, reimbursement, and commercial decisions it needs to support, at global scale.”
The joint offering directly addresses increasing demand from global regulatory agencies and healthcare payers for robust, real-world comparative effectiveness and humanistic outcome data. Together, the companies aim to help life sciences innovators bridge evidence gaps, optimize global market access, and demonstrate therapeutic value to accelerate patient access to specialized therapies.
EVERSANA and Pulse Infoframe will formally showcase their collaborative capabilities and joint evidence frameworks at ISPOR Europe 2026, scheduled for November 8–11, 2026, in Vienna, Austria.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
